Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

(2011) A. W. Tolcher et al.   ANNALS OF ONCOLOGY

MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia

(2011) R. J. Byers et al.   BLOOD

The β-catenin/Tcf4/survivin signaling maintains a less differentiated phenotype and high proliferative capacity of human corneal epithelial progenitor cells

(2011) Rong Lu et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104

(2011) Juliana Benito et al.   PLoS One

Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML

(2010) B. Z. Carter et al.   BLOOD

IAP Regulation of Metastasis

(2010) Swarna Mehrotra et al.   CANCER CELL

An RNAi Screen Identifies Msi2 and Prox1 as Having Opposite Roles in the Regulation of Hematopoietic Stem Cell Activity

(2010) Kristin J. Hope et al.   Cell Stem Cell

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

(2010) D. C. Talbot et al.   CLINICAL CANCER RESEARCH

Failure of Downregulation of Survivin Following Neoadjuvant Radiochemotherapy in Rectal Cancer Is Associated with Distant Metastases and Shortened Survival

(2010) Thilo Sprenger et al.   CLINICAL CANCER RESEARCH

Overexpression of survivin initiates hematologic malignancies in vivo

(2010) S Small et al.   LEUKEMIA

The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML

(2010) Y. Wang et al.   SCIENCE

Variable slope normalization of reverse phase protein arrays

(2009) E. Shannon Neeley et al.   BIOINFORMATICS

Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3

(2009) S. Fukuda et al.   BLOOD

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

(2009) Karl D. Lewis et al.   INVESTIGATIONAL NEW DRUGS

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

AML1/ETO–induced survivin expression inhibits transcriptional regulation of myeloid differentiation

(2008) Mumtaz Yaseen Balkhi et al.   EXPERIMENTAL HEMATOLOGY

Inhibitor of apoptosis proteins in hematological malignancies

(2008) S Fulda   LEUKEMIA